Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations

Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations

The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to s...

Full description

Bibliographic Details
Main Authors: Sherif Elhosseiny, Hassan Al Moussawi, Jean M. Chalhoub, James Lafferty, Liliane Deeb
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2019/4383269
id doaj-31c902b942e04026aee1cf884e27e3e4
record_format Article
spelling doaj-31c902b942e04026aee1cf884e27e3e42020-11-24T21:56:08ZengHindawi LimitedCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/43832694383269Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical ObservationsSherif Elhosseiny0Hassan Al Moussawi1Jean M. Chalhoub2James Lafferty3Liliane Deeb4The Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Cardiology at Staten Island University Hospital, Northwell Health, USAThe Department of Gastroenterology at Staten Island University Hospital, Northwell Health, USAThe introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile.http://dx.doi.org/10.1155/2019/4383269
collection DOAJ
language English
format Article
sources DOAJ
author Sherif Elhosseiny
Hassan Al Moussawi
Jean M. Chalhoub
James Lafferty
Liliane Deeb
spellingShingle Sherif Elhosseiny
Hassan Al Moussawi
Jean M. Chalhoub
James Lafferty
Liliane Deeb
Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
Canadian Journal of Gastroenterology and Hepatology
author_facet Sherif Elhosseiny
Hassan Al Moussawi
Jean M. Chalhoub
James Lafferty
Liliane Deeb
author_sort Sherif Elhosseiny
title Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
title_short Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
title_full Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
title_fullStr Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
title_full_unstemmed Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
title_sort direct oral anticoagulants in cirrhotic patients: current evidence and clinical observations
publisher Hindawi Limited
series Canadian Journal of Gastroenterology and Hepatology
issn 2291-2789
2291-2797
publishDate 2019-01-01
description The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile.
url http://dx.doi.org/10.1155/2019/4383269
work_keys_str_mv AT sherifelhosseiny directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations
AT hassanalmoussawi directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations
AT jeanmchalhoub directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations
AT jameslafferty directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations
AT lilianedeeb directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations
_version_ 1725859277102383104

Similar Items